论文部分内容阅读
无味氯霉素(氯霉素棕榈酸酯)在体内被酯酶水解成氯霉素而发挥作用。它的晶体有 A型、B 型和无定形等几种。本品在体内的吸收和排泄,与药物的晶型和制剂过程中表面活性剂的应用等均有密切关系,但主要与原料晶型有关。本品的 A 晶型在肠道内很难为胃肠的酯酶水解,因而难于吸收,血浓度低,不易达到预期的疗效,故称为无活性晶型。英国副药典(BPC 1968版)、美国药典(USP 19版)都增添了控制无味氯霉素 A 晶型含量的质量标准,规定制剂中 A 晶型不应超过10%。国产无味氯霉素的某些制剂,尽管以往曾有医疗单位反映疗效不满意,但是否与本品的
Odorless chloramphenicol (chloramphenicol palmitate) in the body by esterase hydrolysis into chloramphenicol and play a role. Its crystals are A-type, B-type and amorphous and so on. Absorption and excretion of this product in the body are closely related to the crystal form of the drug and the application of the surfactant in the process of preparation, but are mainly related to the crystal form of the raw material. A crystal form of this product in the intestine is difficult to esterase hydrolysis of the gastrointestinal, which is difficult to absorb, low blood concentration, difficult to achieve the desired effect, it is called inactive crystals. The British Pharmacopoeia (BPC 1968) and USP 19 (19) all add quality standards to control the odorless chloramphenicol A content, which stipulates that Form A should not exceed 10%. Some domestic flavorless chloramphenicol preparations, although in the past have not responded to the medical unit to reflect the efficacy, but whether the product